LCM
HUMA icon

LuminArx Capital Management’s Humacyte HUMA Stock Holding History

LuminArx Capital Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$507K Buy
+650,000
New +$602K 0.23% 54

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

LuminArx Capital Management's HUMA Position: Q2 2026 in Review

LuminArx Capital Management opened a new position in Humacyte (HUMA) in Q2 2026: 650,000 shares worth $507K. The stake represents 0.23% of the portfolio and ranks #54 among its holdings.

161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • LuminArx Capital Management held 650,000 shares of Humacyte worth $507K as of Q2 2026.
  • Humacyte was a new LuminArx Capital Management position in Q2 2026.
  • Humacyte made up 0.23% of LuminArx Capital Management's portfolio in Q2 2026, its #54 holding.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on LuminArx Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.